Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5656119 | 0.94 | PKM (0.61) | PKMKMT2ANPSR1CYP2C9CYP2C19 | |
| SCHEMBL5654961 | 0.90 | NPSR1 (0.72) | KMT2ANPSR1CYP2C9CYP2C19MEN1 | |
| SCHEMBL14457596 | 0.89 | HTR1A (0.50) | PKM | |
| SCHEMBL5666368 | 0.89 | KMT2A (0.51) | PKMKMT2ANPSR1TP53MAPT | |
| SCHEMBL5656677 | 0.89 | ADRA1D (0.60) | KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL5654298 | 0.89 | ADORA2B (0.51) | PKMKMT2ANPSR1MEN1MAPT | |
| SCHEMBL14457602 | 0.86 | MEN1 (0.51) | PKMKMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL14457589 | 0.86 | HTR7 (0.47) | PKM | |
| SCHEMBL5657841 | 0.85 | HTR1A (0.55) | KMT2AMEN1TP53MAPTLMNA | |
| SCHEMBL5655966 | 0.84 | NPSR1 (0.69) | KMT2ANPSR1CYP2C9CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | CEREP (FR) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | HTR4, HTR5A, HTR3C | PKM 1446/4885KMT2A 2124/4885NPSR1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.